NEW YORK – Acrivon Therapeutics has received CLIA certification for its laboratory to test patients and develop companion diagnostics for its targeted therapies. The lab will be located at Acrivon's ...

The gene therapy, which was acquired by Novartis in 2023, is also being tested in a separate Phase I/II trial of pediatric ...

The organization presented data aggregated from multiple clinical trials to explore ctDNA's potential as a surrogate endpoint predictive of treatment benefit in lung and other cancers.

NEW YORK – The US Food and Drug Administration has accepted Roche subsidiary Genentech's new drug application for giredestrant in combination with the mTOR inhibitor Afinitor (everolimus) for estrogen ...

The financing will, in part, support an upcoming Phase IIIb trial of its beleaguered stem cell therapy for amyotrophic lateral sclerosis.

Tagrisso, Imfinzi, Truqap, and Enhertu all reported double-digit sales growth during the fourth quarter and full-year 2025 ...

A study evaluated agreement between 10 AI digital pathology tools in assessing IHC-based HER2 expression and found the most variability in identifying HER2-low samples.

The firm will provide manufacturing and regulatory support as UW prepares an IND submission for its GD2 CAR T-cell therapy.

The company is expecting additional readouts this year from studies of cancer vaccine intismeran autogene, which is being tested in late-stage trials.

NEW YORK – Eli Lilly on Monday said it will share with health authorities results from a Phase III trial of Retevmo (selpercatinib) showing the RET inhibitor improved survival outcomes as an adjuvant ...

NEW YORK – NovaBridge, which rebranded from I-Mab in October, has advanced its CLDN18.2- and 4-1BB- targeting bispecific antibody, givastomig, into a Phase II trial, the company said. That has been a ...

The firm will test the FSHR-targeting lira-cel at up to 100-tmes higher doses after seeing better than expected outcomes at ...